eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | metabolic syndrome x |
| Symptom | |dyslipidemia |
| Sentences | 66 |
| PubMedID- 21274756 | metabolic syndrome is also associated with insulin resistance, dyslipidemia, hypertriglyceridemia, and type 2 diabetes mellitus. |
| PubMedID- 20880339 | Although traditional anti-diabetes agents improve hyperglycaemia, they do so at a cost, which may entail hypoglycemia and increased body weight; exacerbating dyslipidemia, hypertension and components of insulin resistance and metabolic syndrome associated with t2dm-potentially increasing cardiovascular risk. |
| PubMedID- 23554788 | Nafld is associated with dyslipidemia, an integral feature of metabolic syndrome. |
| PubMedID- 21986714 | It is also capable of decreasing the dyslipidemia associated with metabolic syndrome (yoon 2009). |
| PubMedID- 24205230 | At adulthood, the pigs exposed to both maternal under- and overnutrition during the entire pregnancy evidence dyslipidemia, a fourth symptom of the metabolic syndrome. |
| PubMedID- 21468365 | Pitavastatin may allow for more aggressive treatment of mixed dyslipidemia, especially common in patients with metabolic syndrome and diabetes mellitus. |
| PubMedID- 25659889 | Peripheral insulin resistance is a key component of metabolic syndrome associated with obesity, dyslipidemia, hypertension, and type 2 diabetes. |
| PubMedID- 21426238 | Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus. |
| PubMedID- 25383490 | Impaired fasting blood glucose is one of the landmark signs of metabolic syndrome, together with hyperinsulinemia, dyslipidemia, hypertension, and a chronic proinflammatory, pro-oxidative, and prothrombotic environment. |
| PubMedID- 21403658 | dyslipidemia, an important component of the insulin resistance syndrome and type 2 diabetes, is strongly related to cvd risk and is open to therapeutic intervention. |
| PubMedID- 25861250 | The agonists of ppars are therapeutically used to treat dyslipidemia and hyperglycaemia associated with the metabolic syndrome. |
| PubMedID- 25625330 | Hyperglycemia and dyslipidemia are characteristic features of the metabolic syndrome, a serious public health problem with rising prevalence. |
| PubMedID- 20942934 | Tenkanen l' data showed that patients with dyslipidemia and features associated with the metabolic syndrome(bmi and tg in the highest tertiles). |
| PubMedID- 22662254 | Transgenic over-expression of 11β-hsd1 in adipose tissue recapitulates the metabolic syndrome in mice, with visceral obesity, dyslipidemia, insulin resistance/diabetes and hypertension . |
| PubMedID- 21722517 | Lipoprotein lipase (lpl) plays a central role in dyslipidemia and development of metabolic syndrome. |
| PubMedID- 25923694 | Both in vivo and in vitro studies have demonstrated that pparα regulates the expression of some genes involved in lipid metabolism and plays a central role in the control of dyslipidemia associated with the metabolic syndrome . |
Page: 1 2